ReviewOncotarget2019
Role of surgery in gynaecological sarcomas.
Review in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Extended and Repeated Cytoreductive Surgery in Recurrent Uterine Leiomyosarcoma: A Narrative Review.Cancers · 2026Review
- A Challenging Diagnosis of Endometrial Stromal Sarcoma in a 50-Year-Old Patient: Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- A neurosurgical approach to skull metastasis from uterine leiomyosarcoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience.Diseases (Basel, Switzerland) · 2024Article
- Infectious Complications in Laparoscopic Gynecologic Oncology Surgery within an ERAS-Compliant Setting.Journal of personalized medicine · 2024Article
- Thinking Twice about the Cervical Mass: A Case Report of Primary Vaginal Leiomyosarcoma and Review of the Literature.Case reports in obstetrics and gynecology · 2024Article
- Article
- Lung Metastasis From Uterine Leiomyosarcoma: An Asymptomatic Presentation for a Rare Tumor.Cureus · 2023Article
- Primary leiomyosarcoma of the uterine cervix: an unusual case and critical appraisal.Journal of surgical case reports · 2023Article
- Radiomics and Artificial Intelligence in Uterine Sarcomas: A Systematic Review.Journal of personalized medicine · 2021Review
- Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.Cancer chemotherapy and pharmacology · 2021Article
- Assessing immune infiltration and the tumor microenvironment for the diagnosis and prognosis of sarcoma.Cancer cell international · 2020Article
- Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases.Molecular and clinical oncology · 2020Article
- Advances in the management of pediatric genitourinary rhabdomyosarcoma.Translational andrology and urology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynaecological sarcomas account for 3-4% of all gynaecological malignancies and have a poorer prognosis compared to gynaecological carcinomas. Pivotal treatment for early-stage uterine sarcoma is represented by total hysterectomy. Whereas oophorectomy provides survival advantage in endometrial stromal sarcoma is still controversial. When the disease is confined to the uterus, systematic pelvic and para-aortic lymphadenectomy is not recommended. Removal of enlarged lymph-nodes is indicated in case of disseminated or recurrent disease, where debulking surgery is considered the standard of care. Fertility sparing surgery for uterine leiomyosarcoma is not supported by strong evidence, whilst available data on fertility sparing treatment for endometrial stromal sarcoma are more promising. For ovarian sarcomas, in the absence of specific data, it is reasonable to adapt recommendations existing for uterine sarcomas, also regarding the role of lymphadenectomy in both early and advanced stage disease. Specific recommendations on cervical sarcomas' surgery are lacking. Existing data on surgical approach vary from radical hysterectomy to fertility-preserving surgery in the form of trachelectomy or wide local excision, however no definite conclusions can be drafted on the recommended surgical approach. For vulval sarcomas, complete surgical excision with at least 2 cm of free margin is considered to be the primary treatment which is associated with good prognosis. The aim of this review is to provide highest quality evidence to guide gynaecologic oncologists throughout surgical management of gynaecological sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.